On Friday, Shares of TherapeuticsMD Inc (NYSEMKT:TXMD), added 2.79% and closed at $6.81 in the last trading session. The last trading range of the stock ranges between $6.52 and $7.00. TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, recently declared the plan of nine posters and oral presentations at forthcoming medical conferences related to Yuvvexy, the conditionally-approved trade name for TX-004HR, an investigational applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), because of menopause.
The presentations support the results from the Yuvvexy clinical development program and further identify women’s perceptions of VVA and current available treatment options. Additional data to be presented provide new insights about the lack of understanding of VVA as a serious medical condition. The posters and presentations will be made at annual meetings of the International Menopause Society (IMS) on September 28 – October 1 in Prague, Czech Republic, and the North American Menopause Society (NAMS) on October 5-8 in Orlando, Florida.
PulteGroup, Inc. (NYSE:PHM), jumped 1.16% and closed at $20.04 in the last trading session. The last trading range of the stock ranges between $19.70 and $20.08. The company’s Market capitalization is $6.97 Billion with the total Outstanding Shares of 343.62 million. ATLANTA, Sept. 26, 2016 /PRNewswire/ — PulteGroup, Inc. (PHM) recently declared that it will release its third quarter 2016 financial results before the market opens on Thursday, October 20, 2016. The Company will hold a conference call to discuss third quarter results that same day at 8:30 a.m. (ET).
For call participants, the dial-in number is (800) 967-7140 (conference ID 1803689). The call will be recorded and available for audio replay on pultegroupinc.com within 24 hours.
Eli Lilly and Co (NYSE:LLY), jumped 0.65% and closed at $80.26 in the last trading session. The last trading range of the stock ranges between $80.03 and $80.65. During the 52-week trading session the minimum price at which share price traded, registered at $67.88 and reached to max level of $88.48. Eli Lilly and Company (LLY) will highlight clinical and patient-related health outcomes data evaluating Taltz® (ixekizumab) for the treatment of adult patients with moderate-to-severe plaque psoriasis at the annual European Academy of Dermatology and Venereology Congress (EADV), which will take place Sept. 28-Oct. 2, 2016, in Vienna, Austria.
A total of 17 abstracts, counting eight oral abstracts with one late-breaker presentation, will feature sub-analyses from pivotal Phase 3 data of Taltz for the treatment of moderate-to-severe plaque psoriasis across a number of areas.
“EADV represents a tremendous opportunity for dermatologists to exchange information that assists better address unmet needs for patients,” said Dr. Lotus Mallbris, Lilly’s global brand development leader for Taltz. “Lilly is excited to support the evolution of new treatments in dermatology as we share new data for Taltz in the treatment of moderate-to-severe plaque psoriasis.”